Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04513925 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 829
- Enrollment target
NCT04513925 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 829 participants.
The verdict
NCT04513925, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 829 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
Interventions
- DRUG Atezolizumab
- DRUG Durvalumab
- DRUG Tiragolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 829 participants |
| Start Date | 2020-08-24 |
| Est. Completion | 2025-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04513925
The ClinicalTrials.gov registry entry for NCT04513925 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 829 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atezolizumab is the first listed.
NCT04513925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04513925 about?
NCT04513925 is a clinical study titled "A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-base...
What is the current status of trial NCT04513925?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 829 participants. The study started on 2020-08-24. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT04513925?
The interventions under investigation include: Atezolizumab (DRUG), Durvalumab (DRUG), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT04513925?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.